Chan Cheah
@chancheah.bsky.social
Haematologist, Sir Charles Gairdner & Hollywood. Professor, University of Western Australia. Director, Blood Cancer Research WA #lymSM
Pleased to share EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
#lymSM @hemasphere-journal.bsky.social
#lymSM @hemasphere-journal.bsky.social
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
Mantle cell lymphoma (MCL) is a relatively rare B-cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse beha...
onlinelibrary.wiley.com
October 23, 2025 at 4:34 AM
Pleased to share EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
#lymSM @hemasphere-journal.bsky.social
#lymSM @hemasphere-journal.bsky.social
More reasons not to use RGemOx if you have access to Mosun, Glofit and/or pola:
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
October 3, 2025 at 11:55 AM
More reasons not to use RGemOx if you have access to Mosun, Glofit and/or pola:
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
Excellent work Toby Eyre et al on this comprehensive @myesmo.bsky.social
Huge body of work and practical guidance for the staging and management of the breadth of these conditions
#lymphoma #guidelines #lymSM
lnkd.in/gESZfHXY
Huge body of work and practical guidance for the staging and management of the breadth of these conditions
#lymphoma #guidelines #lymSM
lnkd.in/gESZfHXY
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
August 6, 2025 at 2:01 AM
Excellent work Toby Eyre et al on this comprehensive @myesmo.bsky.social
Huge body of work and practical guidance for the staging and management of the breadth of these conditions
#lymphoma #guidelines #lymSM
lnkd.in/gESZfHXY
Huge body of work and practical guidance for the staging and management of the breadth of these conditions
#lymphoma #guidelines #lymSM
lnkd.in/gESZfHXY
Reposted by Chan Cheah
Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL @chancheah.bsky.social #EHA2025 #lymsm #hematology
www.onclive.com/view/glofita...
www.onclive.com/view/glofita...
Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL
Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.
www.onclive.com
July 11, 2025 at 1:14 PM
Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL @chancheah.bsky.social #EHA2025 #lymsm #hematology
www.onclive.com/view/glofita...
www.onclive.com/view/glofita...
Is your CLL and MCL management approach aligned with the latest evidence and patient preferences?
Find out more in this activity bit.ly/4nRN3r3
@medscape.com #lymphoma #medicaleducation #clinicaltrials #leukemia
Find out more in this activity bit.ly/4nRN3r3
@medscape.com #lymphoma #medicaleducation #clinicaltrials #leukemia
July 23, 2025 at 10:35 PM
Is your CLL and MCL management approach aligned with the latest evidence and patient preferences?
Find out more in this activity bit.ly/4nRN3r3
@medscape.com #lymphoma #medicaleducation #clinicaltrials #leukemia
Find out more in this activity bit.ly/4nRN3r3
@medscape.com #lymphoma #medicaleducation #clinicaltrials #leukemia
Reposted by Chan Cheah
It was a pleasure to catch up with @chancheah.bsky.social at #EHA2025 to hear the updated Phase I results of sonrotoclax plus zanubrutinib in patients with R/R CLL/SLL.🩸
Watch the interview here:
👉 buff.ly/TYQfq4h 👈
#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
Watch the interview here:
👉 buff.ly/TYQfq4h 👈
#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
June 25, 2025 at 10:02 AM
It was a pleasure to catch up with @chancheah.bsky.social at #EHA2025 to hear the updated Phase I results of sonrotoclax plus zanubrutinib in patients with R/R CLL/SLL.🩸
Watch the interview here:
👉 buff.ly/TYQfq4h 👈
#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
Watch the interview here:
👉 buff.ly/TYQfq4h 👈
#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
Fastest review I have ever been involved with - written almost entirely on the plane back from #ASH24
#lymSM
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
#lymSM
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma
associated with limited overall survival. Targeting of the B-cell receptor pathway
in relapsed disease with covalent...
ascopubs.org
May 30, 2025 at 11:44 AM
Fastest review I have ever been involved with - written almost entirely on the plane back from #ASH24
#lymSM
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
#lymSM
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
pleased to share this review of CD19 x CD3 bispecific TCE from our group. Kudos to my registrar Harry Hambleton #lymSM
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma www.tandfonline.com/doi/full/10....
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma www.tandfonline.com/doi/full/10....
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma
Follicular lymphoma (FL) is the most common indolent lymphoma. Patients with advanced-stage FL typically respond to therapy, then follow a relapsing/remitting course, with shorter progression-free ...
www.tandfonline.com
May 7, 2025 at 9:09 AM
pleased to share this review of CD19 x CD3 bispecific TCE from our group. Kudos to my registrar Harry Hambleton #lymSM
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma www.tandfonline.com/doi/full/10....
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma www.tandfonline.com/doi/full/10....
Great to see this study of nivolumab and rituximab in follicular lymphoma just out in @bloodadvances.bsky.social
ashpublications.org/bloodadvance...
kudos @elizahawkes.bsky.social #lymSM
ashpublications.org/bloodadvance...
kudos @elizahawkes.bsky.social #lymSM
Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' study
Key Points. Nivolumab priming followed by combination nivolumab and rituximab was well tolerated in treatment naïve follicular lymphoma patients.In this si
ashpublications.org
January 26, 2025 at 9:24 PM
Great to see this study of nivolumab and rituximab in follicular lymphoma just out in @bloodadvances.bsky.social
ashpublications.org/bloodadvance...
kudos @elizahawkes.bsky.social #lymSM
ashpublications.org/bloodadvance...
kudos @elizahawkes.bsky.social #lymSM
Great article about Prof John Seymour @petermaccc.bsky.social in @ash-hematology.bsky.social Clinical News sharing his love of cycling ashpublications.org/ashclinicaln...
🚴♂️
🚴♂️
A Life in Balance: John Seymour, MBBS, PhD | ASH Clinical News | American Society of Hematology
ashpublications.org
December 17, 2024 at 1:17 AM
Great article about Prof John Seymour @petermaccc.bsky.social in @ash-hematology.bsky.social Clinical News sharing his love of cycling ashpublications.org/ashclinicaln...
🚴♂️
🚴♂️
Reposted by Chan Cheah
Great to see this published! Effect of replacing procarbazine for dacarbazine in escBEACOPP for Hodgkin treatment. Hugely beneficial effect on genotoxicity. Really no role for procarbazine in front line Hodgkin nowadays.
#lymsm
www.thelancet.com/journals/lan...
#lymsm
www.thelancet.com/journals/lan...
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for the genomic health of survivors of Hodgkin lymphoma and hereditary consequences for their offspring. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem-cell toxicity while maintaining similar clinical efficacy.
www.thelancet.com
December 12, 2024 at 6:42 PM
Great to see this published! Effect of replacing procarbazine for dacarbazine in escBEACOPP for Hodgkin treatment. Hugely beneficial effect on genotoxicity. Really no role for procarbazine in front line Hodgkin nowadays.
#lymsm
www.thelancet.com/journals/lan...
#lymsm
www.thelancet.com/journals/lan...
Reposted by Chan Cheah
Reposted by Chan Cheah
Reposted by Chan Cheah
Reposted by Chan Cheah
Dr Hou: phase I data for CD19 x CD3 T-cell engaging antibody AZD486 in 3L+ follicular lymphoma. With double step up dosing, CRS was all grade 1, low toci use (13%). Highly active (CR rate 85%) + high rates of uMRD. The 1L study SOUNDTRACK F1 is open at SCGH #lymSM #hemeSky #ASH24
December 8, 2024 at 1:15 AM
Dear @ash-hematology.bsky.social #ASH24… while most of the meeting is incredibly well organised - thank you! - sadly all of the lymphoma sessions have been in rooms which are far too small! 😕
Not the same in the overflow rooms…
Not the same in the overflow rooms…
December 8, 2024 at 12:16 AM
Dear @ash-hematology.bsky.social #ASH24… while most of the meeting is incredibly well organised - thank you! - sadly all of the lymphoma sessions have been in rooms which are far too small! 😕
Not the same in the overflow rooms…
Not the same in the overflow rooms…
Martin Dreyling presents long term update of the TRIANGLE study (European MCL network) Practice changer (if you can access 1L BTKi)
fixed duration ibrutinib in 1L treatment naive mantle cell lymphoma patients leads to superior OS compared with ASCT as a consolidation strategy
#lymSM #hemeSky #ASH24
fixed duration ibrutinib in 1L treatment naive mantle cell lymphoma patients leads to superior OS compared with ASCT as a consolidation strategy
#lymSM #hemeSky #ASH24
December 7, 2024 at 11:24 PM
Reposted by Chan Cheah
Lewis et al: ENRICH study in 1L MCL
- Ibr+ritux vs R-chemo (RCHOP or R-benda)
- 400 pts, >60y
-PFS: prolonged with IR
- Largely driven by benefit over R-CHOP
- Blastoid did not benefit from IR
- OS the same
- 22% cardiac AEs with IR
1st trial to show benefit chemo-free in 1L MCL.
#ASH24 #lymsm
- Ibr+ritux vs R-chemo (RCHOP or R-benda)
- 400 pts, >60y
-PFS: prolonged with IR
- Largely driven by benefit over R-CHOP
- Blastoid did not benefit from IR
- OS the same
- 22% cardiac AEs with IR
1st trial to show benefit chemo-free in 1L MCL.
#ASH24 #lymsm
December 7, 2024 at 10:18 PM
The best way to kick off #ASH24 - on a road bike!
www.strava.com/activities/1... #strava
#lymSM #hemeSKY
www.strava.com/activities/1... #strava
#lymSM #hemeSKY
December 6, 2024 at 6:14 AM
The best way to kick off #ASH24 - on a road bike!
www.strava.com/activities/1... #strava
#lymSM #hemeSKY
www.strava.com/activities/1... #strava
#lymSM #hemeSKY